ProfileGDS5678 / 1416247_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 94% 94% 93% 93% 95% 95% 94% 95% 94% 95% 94% 94% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.1921794
GSM967853U87-EV human glioblastoma xenograft - Control 28.215594
GSM967854U87-EV human glioblastoma xenograft - Control 38.2123694
GSM967855U87-EV human glioblastoma xenograft - Control 48.0367193
GSM967856U87-EV human glioblastoma xenograft - Control 57.9572593
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.2944695
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.2527795
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.1682594
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.2888895
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.2384994
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.3674195
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.2294294
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.1863694
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.2004694